GHRP-2

1. Quick Facts

Category: Growth Hormone Secretagogue

Risk Level: Moderate/High

Research Status: Established Experimental Research

Administration: Subcutaneous Injection

Typical Frequency: 1–3 Times Daily

Estimated Half-Life: Short Plasma Half-Life

Primary Research Interest: Growth Hormone Release / Appetite Regulation / Endocrine Signaling

Important Disclaimer

This material is provided strictly for educational and informational purposes related to peptide research and growth hormone signaling compounds. GHRP-2 is a biologically active growth hormone secretagogue capable of significantly altering growth hormone, cortisol, prolactin, and metabolic signaling pathways. Information presented here should not be interpreted as medical advice, treatment recommendations, or encouragement of unsupervised use.

2. Summary

GHRP-2 (Growth Hormone Releasing Peptide-2) is a synthetic ghrelin receptor agonist and growth hormone secretagogue developed as part of the early generation of GHRP compounds. It is widely researched for its ability to stimulate pulsatile growth hormone release and influence appetite-regulation pathways.

Research interest in GHRP-2 commonly centers around growth hormone release, endocrine signaling, appetite regulation, recovery support, and body-composition applications. Compared with newer secretagogues such as Ipamorelin, GHRP-2 is generally considered more potent but also more likely to influence cortisol, ACTH, prolactin, and hunger signaling.

What People Commonly Claim

Increases growth hormone release
Improves recovery
Improves sleep quality
Increases appetite
Accelerates fat loss
Supports muscle growth
Raises IGF-1 levels
Works synergistically with CJC-1295 and other GHRH analogs

What the Literature Actually Shows

Human studies consistently demonstrate robust growth hormone release.
GHRP-2 activates ghrelin receptors and influences appetite signaling.
Appetite stimulation is well documented in human studies.
Effects on ACTH, cortisol, and prolactin appear more pronounced than with some newer secretagogues.
Growth hormone and endocrine effects are well supported.
Many physique and body-composition claims are extrapolated from hormonal changes rather than direct outcome studies.
Long-term safety data remain limited.

CKF Transparency Note: GHRP-2 is one of the most extensively studied members of the classic growth hormone secretagogue family. Human research consistently demonstrates robust stimulation of growth hormone release, and studies also support effects on appetite regulation through ghrelin-receptor signaling. However, many physique, performance, and recovery claims commonly discussed within peptide communities are extrapolated from hormonal changes rather than direct long-term outcome studies. Compared with newer secretagogues such as Ipamorelin, GHRP-2 appears more likely to influence appetite, ACTH, cortisol, and prolactin signaling in addition to growth hormone release.

3. Reconstitution Guide

Vial Size: 10 mg
Dilutant Type: BAC Water
Amount of Dilutant Added: 3 mL
Final Concentration: 3.33 mg/mL

At this concentration:
• 100 mcg = 0.030 mL (3.0 units)
• 300 mcg = 0.090 mL (9.0 units)

*Different vial sizes may limit reconstitution volume. If your product differs from the specifications listed here, please use the Peptide Calculator to calculate custom concentrations and dosing protocols.

4. Route of Administration

GHRP-2 is most commonly administered as a subcutaneous injectable growth hormone secretagogue.

Primary Route: SubQ Injection
Preferred Timing: Commonly administered in fasted states
Administration Notes: Frequently researched in conjunction with GHRH analogs such as CJC-1295 or Modified GRF 1-29 to amplify pulsatile growth hormone signaling.

5. Typical Research Protocols

Product Strength: 3.33 mg/mL
Typical Delivered Amount: 100–300 mcg per dose
Frequency: 1–3 times daily
Cycle Length: 8–16 weeks on / 2–4 weeks off
Special Notes: GHRP-2 is often discussed as one of the more potent appetite-stimulating secretagogues. Researchers frequently pair it with GHRH analogs in an effort to increase pulsatile growth hormone release. Because GHRP-2 may increase cortisol and prolactin more noticeably than compounds such as Ipamorelin, conservative dosing and periodic reassessment are commonly emphasized.

6. Mechanism of Action

GHRP-2 functions primarily through activation of the ghrelin receptor (GHS-R1a), stimulating pulsatile growth hormone release from the pituitary gland while also influencing appetite-regulation pathways.

Potential downstream effects discussed in research include:

Growth hormone release signaling
Ghrelin receptor activation
Appetite stimulation
IGF-1 pathway support
ACTH and cortisol signaling effects
Prolactin signaling effects
Metabolic pathway modulation

Unlike Ipamorelin, which was designed to minimize off-target endocrine effects, GHRP-2 appears to produce broader neuroendocrine activation.

7. Potential Benefits

Potential increase in growth hormone signaling
Enhanced recovery support
Possible sleep-quality improvements
Potential appetite enhancement
Potential body-composition support
Possible synergistic effects with GHRH analogs
Potential IGF-1 elevation

8. Potential Risks / Side Effects

Moderate/High

Increased hunger
Water retention
Elevated cortisol signaling
Elevated prolactin signaling
Numbness or tingling
Fatigue
Potential insulin-sensitivity changes
Potential endocrine dysregulation with prolonged use

9. Half-Life

GHRP-2 is generally considered a short-acting growth hormone secretagogue with a relatively brief plasma half-life.

Despite this short duration, downstream growth hormone, IGF-1, and endocrine signaling effects may persist substantially longer than measurable circulating peptide concentrations.

10. Storage Information

Store refrigerated before and after reconstitution
Protect from direct light exposure
Avoid repeated freeze-thaw cycles
Maintain sterile handling practices during preparation

11. Contraindications / Warnings

Active cancer concerns
Uncontrolled diabetes
Pregnancy or breastfeeding
Known hypersensitivity to peptide compounds
Use alongside multiple hormone-modulating compounds without appropriate oversight

12. Further Study

GHRP-2 is among the better-studied classic growth hormone secretagogues. Readers interested in the compound should focus on the distinction between well-established endocrine effects and the more speculative body-composition claims frequently discussed within peptide communities.

Tier 1 — Essential Reading

Growth Hormone Releasing Peptide-2 (GHRP-2), Like Ghrelin, Increases Food Intake in Healthy Men
Human study demonstrating appetite stimulation and ghrelin-like effects.

Synthetic Growth Hormone-Releasing Peptides (GHRPs)
Comprehensive review covering GHRP-2, GHRP-6, Hexarelin, and related compounds.

The Safety and Efficacy of Growth Hormone Secretagogues
Broad review of efficacy, safety, appetite effects, and body-composition claims.

Tier 2 — Advanced Reading

Evaluation of Hypothalamic–Pituitary–Adrenal Axis by GHRP-2
Examines ACTH and cortisol responses associated with GHRP-2 administration.

Growth Hormone Response to Growth Hormone-Releasing Peptide-2
Mechanistic research examining growth hormone release pathways.

Tier 3 — Context & Comparison

Clinical Usefulness of the Growth Hormone–Releasing Peptide-2 Test
Illustrates the diagnostic value of GHRP-2 as a growth hormone stimulation test.

Current Evidence Gaps

Large-scale long-term safety studies
Direct body-composition outcome studies
Long-term metabolic effects
Comparative studies versus Ipamorelin
Optimal long-term cycling strategies
Long-term endocrine adaptation data

13. Research References

PubMed
PubMed Central (PMC)
NIH Publications
Endocrinology literature
Growth hormone physiology research
Peer-reviewed metabolism journals

14. Last Reviewed

June 2026